Your browser doesn't support javascript.
Potential therapeutic applications of extracellular vesicles in the immunopathogenesis of COVID-19.
Motallebnezhad, Morteza; Omraninava, Melodi; Esmaeili Gouvarchin Ghaleh, Hadi; Jonaidi-Jafari, Nematollah; Hazrati, Ali; Malekpour, Kosar; Bagheri, Yasser; Izadi, Morteza; Ahmadi, Majid.
  • Motallebnezhad M; Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Omraninava M; Department of Infectious Disease, Faculty of Medical Sciences, Sari Branch, Islamic Azad University, Sari, Iran.
  • Esmaeili Gouvarchin Ghaleh H; Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Jonaidi-Jafari N; Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Hazrati A; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Malekpour K; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Bagheri Y; Immunology Department, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
  • Izadi M; Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: morteza_izadii@yahoo.com.
  • Ahmadi M; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: m.ahmadi6892@gmail.com.
Pathol Res Pract ; 241: 154280, 2023 Jan.
Article in English | MEDLINE | ID: covidwho-2159729
ABSTRACT
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19) which has emerged as a global health crisis. Recently, more than 50 different types of potential COVID-19 vaccines have been developed to elicit a strong immune response against SARS-CoV-2. However, genetic mutations give rise to the new variants of SARS-CoV-2 which is highly associated with the reduced effectiveness of COVID-19 vaccines. There is still no efficient antiviral agent to specifically target the SARS-CoV-2 infection and treatment of COVID-19. Therefore, understanding the molecular mechanisms underlying the pathogenesis of SARS-CoV-2 may contribute to discovering a novel potential therapeutic approach to the management of COVID-19. Recently, extracellular vesicle (EV)-based therapeutic strategies have received great attention on account of their potential benefits in the administration of viral diseases. EVs are extracellular vesicles containing specific biomolecules which play an important role in cell-to-cell communications. It has been revealed that EVs are involved in the pathogenesis of different inflammatory diseases such as cancer and viral infections. EVs are released from virus-infected cells which could mediate the interaction of infected and uninfected host cells. Hence, these extracellular nanoparticles have been considered a novel approach for drug delivery to mediate the treatment of a wide range of diseases including, COVID-19. EVs are considered a cell-free therapeutic strategy that could ameliorate the cytokine storm and its complications in COVID-19 patients. Furthermore, EV-based cargo delivery such as immunomodulatory agents in combination with antiviral drugs may have therapeutic benefits in patients with SARS-CoV-2 infection. In this review, we will highlight the potential of EVs as a therapeutic candidate in the diagnosis and treatment of COVID-19. Also, we will discuss the future perspectives regarding the beneficial effects of Evs in the development of COVID-19 vaccines.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Extracellular Vesicles / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Pathol Res Pract Year: 2023 Document Type: Article Affiliation country: J.prp.2022.154280

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Extracellular Vesicles / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Pathol Res Pract Year: 2023 Document Type: Article Affiliation country: J.prp.2022.154280